Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Ann Surg Oncol. 2016 Sep 23;24(2):398–406. doi: 10.1245/s10434-016-5571-y

Figure 1.

Figure 1

Flowchart showing the treatment of the primary, and sites and treatment of isolated locoregional recurrence (ILRR), starting with all patients enrolled and ending with the 15 patients who experienced a second-ILRR in the CALOR trial.